Myat A - Search Results

1

Survival relative to pacemaker status after transcatheter aortic valve implantation.

Myat A, Mouy F, Buckner L, Cockburn J, Baumbach A, MacCarthy P, Banning AP, Curzen N, Hilling-Smith R, Blackman DJ, Mullen M, de Belder M, Cox I, Kovac J, Manoharan G, Zaman A, Muir D, Smith D, Brecker S, Turner M, Khogali S, Malik IS, Alsanjari O, D'Auria F, Redwood S, Prendergast B, Trivedi U, Robinson D, Ludman P, de Belder A, Hildick-Smith D. Myat A, et al. Catheter Cardiovasc Interv. 2021 Sep;98(3):E444-E452. doi: 10.1002/ccd.29498. Epub 2021 Jan 27. Catheter Cardiovasc Interv. 2021. PMID: 33502784

2

Physiological assessment of coronary haemodynamics: fractional flow reserve and beyond.

Myat A, Asrress KN, McConkey H, Redwood SR. Myat A, et al. EuroIntervention. 2012 Feb;7(10):1236-7. doi: 10.4244/EIJV7I10A196. EuroIntervention. 2012. PMID: 22334322 Free article. No abstract available.

3

Transcatheter aortic valve implantation: revolution and evolution 10 years on.

Myat A, Hildick-Smith D, Young C, Thomas M, Redwood SR. Myat A, et al. Heart. 2012 Nov;98 Suppl 4:iv1-6. doi: 10.1136/heartjnl-2012-303110. Heart. 2012. PMID: 23143120 No abstract available.

4

Resistant hypertension.

Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Myat A, et al. BMJ. 2012 Nov 20;345:e7473. doi: 10.1136/bmj.e7473. BMJ. 2012. PMID: 23169802 Review. No abstract available.

5

Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications.

Myat A, Redwood SR, Qureshi AC, Thackray S, Cleland JG, Bhatt DL, Williams B, Gersh BJ. Myat A, et al. Circ Cardiovasc Interv. 2013 Apr;6(2):184-97. doi: 10.1161/CIRCINTERVENTIONS.112.000037. Circ Cardiovasc Interv. 2013. PMID: 23591420 Review. No abstract available.

6

Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention?

Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Gershlick AH, et al. Among authors: myat a. Lancet. 2013 Aug 17;382(9892):624-32. doi: 10.1016/S0140-6736(13)61454-3. Lancet. 2013. PMID: 23953386 Review.

7

What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention?

Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. Curzen N, et al. Among authors: myat a. Lancet. 2013 Aug 17;382(9892):633-43. doi: 10.1016/S0140-6736(13)61453-1. Lancet. 2013. PMID: 23953387 Review.

8

Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation.

Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Myat A, et al. Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1029-49. doi: 10.1586/14779072.2013.815423. Expert Rev Cardiovasc Ther. 2013. PMID: 23984927 Review.

9

Diabetes, incretin hormones and cardioprotection.

Myat A, Redwood SR, Gersh BJ, Yellon DM, Marber MS. Myat A, et al. Heart. 2014 Oct;100(19):1550-61. doi: 10.1136/heartjnl-2012-303242. Epub 2014 Apr 19. Heart. 2014. PMID: 24747994 No abstract available.

10

Percutaneous circulatory assist devices for high-risk coronary intervention.

Myat A, Patel N, Tehrani S, Banning AP, Redwood SR, Bhatt DL. Myat A, et al. JACC Cardiovasc Interv. 2015 Feb;8(2):229-244. doi: 10.1016/j.jcin.2014.07.030. JACC Cardiovasc Interv. 2015. PMID: 25700745 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

59 results

Search Page